Document is current
Any future updates will be listed below
-
Authors
Flaherty, Kevin R
Brown, Kevin K
Wells, Athol U
Clerisme-Beaty, Emmanuelle
Collard, Harold R
Cottin, Vincent
Devaraj, Anand
Inoue, Yoshikazu
Le Maulf, Florence
Richeldi, Luca
Schmidt, Hendrik
Walsh, Simon
Mezzanotte, William
Schlenker-Herceg, Rozsa
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02999178 at ClinicalTrials.govDocuments that mention this clinical trial
Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial
https://doi.org/10.1186/s12931-023-02371-z
Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
https://doi.org/10.1136/bmj-2021-066354
P163 A multicentre retrospective cohort comparison of aetiology and survival in patients with chronic hypersensitivity pneumonitis versus idiopathic pulmonary fibrosis
https://doi.org/10.1136/thorax-2018-212555.321
Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
https://doi.org/10.1186/s12931-022-01974-2
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease
https://doi.org/10.1136/bmjresp-2017-000212
Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases
https://doi.org/10.1136/bmjresp-2021-001167
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim
